journal article·2017-07

Frizzled7 Antibody‐Functionalized Nanoshells Enable Multivalent Binding for Wnt Signaling Inhibition in Triple Negative Breast Cancer Cells

Rachel S. Riley, Emily S. Day

Small· Volume 13· Issue 26
Publisher page

Abstract

Antibodies that antagonize cell signaling pathways specific to their targeted receptor are invaluable tools to study and treat malignancies, but their utility is limited by high production costs and treatment dosages. Researchers have shown that antibodies conjugated to nanoparticles display increased affinity for their target relative to freely delivered antibodies due to multivalency, and this study investigates how this multivalency can enable antibody–nanoparticle conjugates to inhibit oncogenic cell signaling more effectively than freely delivered antibodies. This effect was evaluated using triple negative breast cancer (TNBC) cells that are characterized by hyperactive Wnt signaling mediated through overexpressed Frizzled7 (FZD7) transmembrane receptors. Through analysis of the expression of β‐catenin and Axin2, two downstream targets in the Wnt pathway, the results demonstrate that FZD7 antibody–nanoshell conjugates (FZD7‐NS) are drastically more effective at inhibiting Wnt signaling in TNBC cells than freely delivered FZD7 antibodies. Additionally, cells treated with FZD7‐NS, but not cells treated with freely delivered FZD7 antibodies, have decreased viability, indicating the therapeutic potential of this technology. The results demonstrate that antibody‐functionalized nanoparticles can exploit multivalency for improved signal cascade interference over free antibodies, and this may ultimately permit lower antibody dosages to be administered to study signaling pathways or to manage diseases.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Wnt/β-catenin signaling in development and cancer · Tissue Engineering and Regenerative Medicine · Nerve injury and regeneration

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering University of Delaware 161 Colburn Lab, 150 Academy Street Newark DE 19716 USA

Department of Materials Science and Engineering University of Delaware Newark DE 19716 USA

Helen F. Graham Cancer Center and Research Institute Newark DE 19713 USA

Funding

University of Delaware Research Foundation · American Cancer Society · National Institute of General Medical Sciences

References (46)

Show source-provided references
1. 10.1126/science.124114510.1126/science.1241145 ↗
2. Scott A. M. · Cancer Immun. · 2012 · 12 · 1
3. 10.1038/nrc323610.1038/nrc3236 ↗
4. 10.1080/0785389080269884210.1080/07853890802698842 ↗
5. 10.2165/00024669-200605010-0000310.2165/00024669-200605010-00003 ↗
6. 10.1038/nrc90310.1038/nrc903 ↗
7. 10.1038/nbt115910.1038/nbt1159 ↗
8. 10.1007/s12032-013-0653-110.1007/s12032-013-0653-1 ↗
9. 10.1177/089719001244206210.1177/0897190012442062 ↗
10. 10.1016/j.cell.2012.05.01210.1016/j.cell.2012.05.012 ↗
11. 10.1002/jcb.2335010.1002/jcb.23350 ↗
12. 10.1038/nrn267410.1038/nrn2674 ↗
13. 10.1038/nrc341910.1038/nrc3419 ↗
14. 10.1038/nature0331910.1038/nature03319 ↗
15. 10.1128/MCB.22.4.1184-1193.200210.1128/MCB.22.4.1184-1193.2002 ↗
16. 10.1128/MCB.22.4.1172-1183.200210.1128/MCB.22.4.1172-1183.2002 ↗
17. 10.1073/pnas.120301510910.1073/pnas.1203015109 ↗
18. 10.1038/sj.onc.121005910.1038/sj.onc.1210059 ↗
19. 10.1016/j.cellsig.2011.12.00910.1016/j.cellsig.2011.12.009 ↗
20. 10.1038/onc.2011.14510.1038/onc.2011.145 ↗
21. 10.1038/onc.2010.54910.1038/onc.2010.549 ↗
22. 10.1073/pnas.112006810910.1073/pnas.1120068109 ↗
23. OncoMed Pharmaceuticals Inc.ClinicalTrials.gov[Internet] National Library of Medicine Betheda MD2013 https://clinicaltrials.gov/ct2/show/NCT02005315 NLM identifier: NCT02005315 (cited March 2017).
24. 10.1007/s10549-010-0811-510.1007/s10549-010-0811-5 ↗
25. 10.2147/nano.2006.1.2.14910.2147/nano.2006.1.2.149 ↗
26. 10.1021/mp400469910.1021/mp4004699 ↗
27. 10.1021/acsnano.5b0513810.1021/acsnano.5b05138 ↗
28. 10.1038/nnano.2008.3010.1038/nnano.2008.30 ↗
29. 10.1016/j.jconrel.2011.08.01410.1016/j.jconrel.2011.08.014 ↗
30. 10.1126/scitranslmed.300683910.1126/scitranslmed.3006839 ↗
31. 10.1101/gad.257394.11410.1101/gad.257394.114 ↗
32. Ahmad I. · Cancer Res. · 1992 · 52 · 4817
33. Park J. W. · Clin. Cancer Res. · 2002 · 8 · 1172
34. 10.1021/bc900221210.1021/bc9002212 ↗
35. 10.2217/nnm.11.18910.2217/nnm.11.189 ↗
36. 10.1177/109158181560017010.1177/1091581815600170 ↗
37. 10.1177/15330346040030010410.1177/153303460400300104 ↗
38. 10.1364/OL.30.00101210.1364/OL.30.001012 ↗
39. 10.1117/1.308155610.1117/1.3081556 ↗
40. 10.1016/S0009-2614(98)00277-210.1016/S0009-2614(98)00277-2 ↗
41. 10.1088/0957-4484/19/31/31510210.1088/0957-4484/19/31/315102 ↗
42. 10.1021/acs.bioconjchem.6b0052310.1021/acs.bioconjchem.6b00523 ↗
43. 10.1021/cr300262710.1021/cr3002627 ↗
44. 10.1007/s00204-010-0546-410.1007/s00204-010-0546-4 ↗
45. 10.1371/journal.pone.012233310.1371/journal.pone.0122333 ↗
46. 10.1021/la00033a01010.1021/la00033a010 ↗